← Back to Search

SABR for Metastatic Cancer

N/A

Waitlist Available

Research Sponsored by Lawson Health Research Institute

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Age 18 or older

Eastern Cooperative Oncology Group (ECOG) performance status 0-2

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 5 years

Awards & highlights

Study Summary

This trial is testing whether a type of radiation therapy called SABR can help people with oligo-progressive metastatic cancers live longer without their disease getting worse.

Who is the study for?

Adults with Non-Small Cell Lung Cancer (NSCLC) showing limited progression in up to 5 lesions, who've had a positive initial response or stable disease from recent systemic therapy. Not eligible if they have serious conditions like scleroderma, prior radiotherapy where treatment is needed, malignant pleural effusion, risk of spinal cord compression by the tumor, or can't treat all progressing sites.Check my eligibility

What is being tested?

The STOP Trial tests Stereotactic Ablative Radiotherapy (SABR) against standard cancer care for patients whose metastatic cancer has progressed only in a few areas. Participants are randomly chosen to receive either SABR or continue their current treatment and monitored for further disease progression.See study design

What are the potential side effects?

Potential side effects of SABR may include skin reactions at the treatment site, fatigue, short-term pain or discomfort post-treatment. Standard care treatments' side effects vary based on specific therapies but often include nausea, fatigue, and hair loss.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am 18 years old or older.

Select...

I am able to get out of my bed or chair and move around.

Select...

My cancer has grown despite treatment, according to specific criteria.

Select...

I have no more than 3 spreading tumors in one organ and no more than 5 in total.

Select...

I have a new cancer spread that is at least 5mm big.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and 5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Progression-Free Survival

Secondary outcome measures

Duration of current systemic agent treatment after SABR

Lesional Control Rate

Location of sites of further progression after SABR

+4 more

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Stereotactic Ablative Radiotherapy (SABR)Experimental Treatment1 Intervention

SABR is delivered to all sites of progressive disease with continuation of current systemic agents. Further oligo-progressive lesions may be treated with SABR if possible. Upon progression at sites not amenable to SABR, the patient may receive any of the options in Arm 1.

Group II: Standard of Care TreatmentActive Control1 Intervention

Patient treatment may include the following 3 options, at the discretion of the treating physicians: Continue with current systemic agent(s) Observation Switch to next-line treatment

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Stereotactic Ablative Radiotherapy (SABR)

2015

N/A

~190

0 / 5Eligibility criteria met

Find a Location

Who is running the clinical trial?

Lawson Health Research InstituteLead Sponsor

656 Previous Clinical Trials

413,338 Total Patients Enrolled

Media Library

Standard of Care Treatment Clinical Trial Eligibility Overview. Trial Name: NCT02756793 — N/A

Cancer Clinical Trial 2023: Standard of Care Treatment Highlights & Side Effects. Trial Name: NCT02756793 — N/A

Standard of Care Treatment 2023 Treatment Timeline for Medical Study. Trial Name: NCT02756793 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are new participants being welcomed for this research project?

"As per the information hosted on clinicaltrials.gov, no participants are being sought at this time. This trial was first listed in October 2016 and underwent its last update in August 2022; however there remain over 3000 other studies actively recruiting patients right now."

Answered by AI

In what specific geographic areas is this experiment taking place?

"At the present moment, 7 clinical trial sites are recruiting patients. These locations span from Victoria to London and Prince George among several others. It is paramount that you select a nearby site so as to reduce any possible travel expenses incurred during your participation in this study."

Answered by AI

Recent research and studies

Clinical Colorectal CancerJournal

Metastasis-directed Radiotherapy for Oligoprogressive or Oligopersistent Metastatic Colorectal Cancer

Lee, Jeongshim, Woong Sub Koom, Hwa Kyung Byun, Gowoon Yang, Mi Sun Kim, Eun Jung Park, Joong Bae Ahn, et al.. 2022. “Metastasis-directed Radiotherapy for Oligoprogressive or Oligopersistent Metastatic Colorectal Cancer”. Clinical Colorectal Cancer. Elsevier BV. doi:10.1016/j.clcc.2021.10.009.

clinicaltrials.govStudy

Stereotactic Radiotherapy for Oligo-Progressive Metastatic Cancer (The STOP Trial)

David Palma 2016. "Stereotactic Radiotherapy for Oligo-Progressive Metastatic Cancer (The STOP Trial)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02756793.